Biogen Idec Initiates Phase III Clinical Program of Oral Compound ...
Business Wire (press release) - San Francisco,CA,USA
Endpoints of both studies include evaluating the effect of BG-12 on measurements of clinical relapse, the progression of disability, and various MRI ...
See all stories on this topic

Market Report -- In Play (WIRES)
MSN Money - USA
Biogen Idec (BIIB) announces that it has initiated the Phase III clinical program of BG-12, an oral fumarate in development for relapsing-remitting multiple ...